Current Funding Opportunities
- External Funding
- Internal Grant Opportunities
The fund will facilitate the advancement of innovative basic science, translational or clinical research to advance the understanding and treatment of Myelodysplastic Syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal hematopoiesis of indeterminate potential (CHIP).
The foundation will consider proposals from individuals at university, college, hospital, or laboratory institutions for support of research in MDS or related disorders in two types:
- Early Career Awards
- Established Investigator Awards
Letter of Intent (LOI) Deadline: LOIs are accepted on a rolling basis.
Fast Funding for COVID-19 Science
If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant.
Deadline: Fast Grant decisions are made in under 48 hours. Apply Now!
The FY20 Defense Appropriations Act provides funding to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research. Pre-application and application deadlines will be available when the Program Announcements are released.Learn more about the DoD Lung Award>>
3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2)
Through this FOA, the NCI, as a part of its Beau Biden Cancer Moonshot Initiative, invites submission of applications requesting support for projects that will accelerate cancer research.
Application Deadline: November 9, 2020
NCI Pediatric In Vivo Testing Program (U01)
- Concept Award – Letter of Intent Due: November 12, 2020
- Idea Development Award – Letter of Intent Due: November 12, 2020
- Resource and Community Development Award – Letter of Intent Due: November 12, 2020
Alex's Lemonade Stand RUNX1 Early Career Investigator Grant
This grant is a 3-year award designed to fund research in strategies leading to the development of therapies to prevent the transition from pre-leukemia to leukemia for patients with RUNX1-FDP.
Application Deadline: December 16, 2020